We are live on ! Find out more
RNAC icon

Cartesian Therapeutics
RNAC

98 hedge funds and large institutions have $245M invested in Cartesian Therapeutics in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 38 increasing their positions, 27 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

288% more call options, than puts

Call options by funds: $5.25M | Put options by funds: $1.35M

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

59% more capital invested

Capital invested by funds: $154M → $245M (+$91.3M)

41% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 27

23% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 13

3% more funds holding

Funds holding: 95 → 98 (+3)

0.04% more ownership

Funds ownership: 1.56% → 1.61% (+0.04%)

Holders
98
Holders Change
+3
Holders Change %
+3.16%
% of All Funds
1.72%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
16
Increased
38
Reduced
27
Closed
13
Calls
$5.25M
Puts
$1.35M
Net Calls
+$3.9M
Net Calls Change
+$4.11M

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$6.35M
2
N
Nuveen
North Carolina
+$6.01M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$4.1M
4
ACP
Acuta Capital Partners
California
+$3.41M
5
BlackRock
BlackRock
New York
+$3.18M

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$4.96M
2
BI
BVF Inc
California
-$3.83M
3
Renaissance Technologies
Renaissance Technologies
New York
-$2.84M
4
6CM
683 Capital Management
New York
-$2.17M
5
MP
Mangrove Partners
Connecticut
-$2.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$28.2M +$3.18M +25,593 +14%
Vanguard Group
2
Vanguard Group
Pennsylvania
$22.4M -$231K -1,857 -1%
AG
3
Artal Group
Luxembourg
$20.4M – – –
BC
4
Boxer Capital
California
$14.9M – – –
MWNA
5
Marshall Wace North America
New York
$13.1M +$40K +322 +0.3%
PVMCV
6
Polaris Venture Management Co V
Massachusetts
$12.6M – – –
BI
7
BVF Inc
California
$10.8M -$3.83M -30,832 -28%
Goldman Sachs
8
Goldman Sachs
New York
$9.62M +$6.35M +51,185 +260%
Jacobs Levy Equity Management
9
Jacobs Levy Equity Management
New Jersey
$9.42M +$4.1M +33,048 +91%
N
10
Nuveen
North Carolina
$8.39M +$6.01M +48,422 +361%
Two Sigma Advisers
11
Two Sigma Advisers
New York
$8.1M +$579K +4,660 +8%
Two Sigma Investments
12
Two Sigma Investments
New York
$7.54M -$212K -1,706 -3%
JP Morgan Chase
13
JP Morgan Chase
New York
$7.04M +$2.33M +18,761 +57%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$6.33M +$851K +6,852 +17%
State Street
15
State Street
Massachusetts
$5.43M +$280K +2,256 +6%
Millennium Management
16
Millennium Management
New York
$5.07M +$2.01M +16,177 +76%
Fidelity Investments
17
Fidelity Investments
Massachusetts
$4.67M – – –
ECM
18
Endurant Capital Management
California
$4.13M -$326K -2,629 -8%
ACP
19
Acuta Capital Partners
California
$3.72M +$3.41M +27,433 New
Morgan Stanley
20
Morgan Stanley
New York
$3.72M -$2.06M -16,566 -38%
Deutsche Bank
21
Deutsche Bank
Germany
$3.47M +$172K +1,386 +6%
Northern Trust
22
Northern Trust
Illinois
$3.32M -$271K -2,181 -8%
AQR Capital Management
23
AQR Capital Management
Connecticut
$1.88M +$35.5K +286 +2%
CM
24
CM Management
Florida
$1.81M +$310K +2,500 +23%
CA
25
Cetera Advisors
Colorado
$1.78M +$653K +5,257 +67%
1
2 3 4 5

RNAC Hedge Fund Activity: Q1 2021 in Review

98 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q1 2021, worth a combined $245M — up 59% from $154M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new RNAC positions and 13 closed out — a net gain of 3 holders — while 38 added to existing stakes and 27 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $6.35M. The largest seller was Armistice Capital, exiting entirely with an estimated $4.96M sold.

  • 98 institutional investors held Cartesian Therapeutics (RNAC) as of Q1 2021, up from 95 in Q4 2020.
  • Funds reported $245M of Cartesian Therapeutics stock for Q1 2021, up 59% quarter-over-quarter.
  • 16 funds opened new Cartesian Therapeutics positions in Q1 2021 and 13 closed out, a net change of +3 holders.
  • The largest Cartesian Therapeutics buyer in Q1 2021 was Goldman Sachs, an estimated $6.35M added.
  • The largest Cartesian Therapeutics seller in Q1 2021 was Armistice Capital, an estimated $4.96M sold.

Based on aggregated 13F filings for Q1 2021.